Menu
Recruiting NCT06520982

Early Neurovascular Adaptations in Aging Women

Early Phase I Interventional Women Sympathetic Nervous System Aging Blood Flow

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Norepinephrine, Isoproterenol, Acetylcholine, Nitroprusside.
Who it may be relevant to
Registry conditions: Women, Sympathetic Nervous System, Aging, Blood Flow. Basic parameters: 18 years — 70 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Our goal is to enhance our understanding of early vascular adaptations in aging women with an emphasis on the sympathetic nervous system.

Interventions

  • Drug Norepinephrine
    Infused intra-arterially in a dose-response fashion
  • Drug Isoproterenol
    Infused intra-arterially in a dose-response fashion
  • Drug Acetylcholine
    Infused intra-arterially in a dose-response fashion
  • Drug Nitroprusside
    Infused intra-arterially in a dose-response fashion
  • Drug Estrogen
    Infused intra-arterially

Primary outcome measures

  • Magnitude of forearm blood flow [Time frame: Change from baseline during infusion]

Eligibility criteria

Inclusion criteria

  • Assigned female at birth (AFAB)
  • 18-70 years of age

Exclusion criteria

  • Assigned male at birth (AMAB)
  • Pregnancy, breastfeeding
  • Body mass index ≥30 kg/m2
  • Taking medications known to affect metabolic, autonomic, and/or respiratory function
  • Oral hormonal contraception in last 6 month
  • History of hormone replacement therapy
  • History of hyster- or oophor-ectomy
  • Current smoking/Nicotine use
  • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
  • Chronic disease
  • Blood pressure ≥140/90 mmHg
  • Communication barriers

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of Missouri-Columbia — Columbia

Identifiers

NCT: NCT06520982 · 2109189

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗